Clobetasol propionate ophthalmic suspension 0.05% for postoperative inflammation and pain after ocular surgery is now commercially available in the U.S., according to a press release from Eyenovia.
“The commercial launch of clobetasol represents a significant milestone for our company, and as the first new ophthalmic steroid to be approved in more than 15 years, a meaningful advancement in the field of ocular surgery,” Michael Rowe, the company’s CEO, said in the release. “With its efficacy and safety profile, convenient twice-a-day dosing regimen and streamlined